BlackRock, Inc. Reports 6.4% Ownership in Avidity Biosciences, Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, reporting a 6.4% ownership in Avidity Biosciences, Inc. as of September 30, 2025. The filing indicates that BlackRock beneficially owns 8,631,771 shares of Avidity Biosciences' common stock, with sole voting power over 8,455,367 shares and sole dispositive power over all 8,631,771 shares. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the common stock, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director of BlackRock, Inc., and was filed on October 17, 2025.